According to the KPMG report, Hong Kong's initial public offering is expected to raise HK$272.1 billion in 2025, an increase of 210% year-on-year, ranking first in the world. According to the report, Hong Kong has completed 17 “A+H” listings so far this year, the highest in history. The amount raised accounts for half of the year, further confirming Hong Kong's unique advantages as a bridge between mainland China and international capital markets. Meanwhile, Hong Kong completed the listing of 14 unprofitable biotech companies, a significant increase from 4 last year; another 3 specialty technology companies were listed, which was the same as last year.

According to the KPMG report, Hong Kong's initial public offering is expected to raise HK$272.1 billion in 2025, an increase of 210% year-on-year, ranking first in the world. According to the report, Hong Kong has completed 17 “A+H” listings so far this year, the highest in history. The amount raised accounts for half of the year, further confirming Hong Kong's unique advantages as a bridge between mainland China and international capital markets. Meanwhile, Hong Kong completed the listing of 14 unprofitable biotech companies, a significant increase from 4 last year; another 3 specialty technology companies were listed, which was the same as last year.